Receptor Life Science

[Deleted]

If this deal has anything to do with POT I will shut up immediately. Smoking POT is worse then cigarettes, edibles are way too strong I always said TS would be great for pot

[rockstarrick]

I hope this isn't a duplicate

From bigkid via YMB 

From Matt on Twitter
FAQ: Technosphere® licensing agreement announced by MannKind™, January 21, 2016
What was announced?
MannKind announced January 21, 2016, that it has entered a proof of concept technology
licensing agreement with an independent company, Receptor Life Sciences, Inc., to use
MannKind’s Technosphere technology as the platform upon which the licensee will develop its
pharmaceutical product.
When does the agreement begin and what are the key milestones?
The agreement is effective as of January 20, 2016. As is typical with development deals of this
sort, up-front money is minimal, as such payments are reflective of the work already done by
the licensor and the risks taken by the licensee. At this point, we have spent little and risked
less in validating this possibility. Most of this work is still ahead of us. Even then, our costs are
largely confined to supporting their efforts using existing personnel, so our incremental out of
pocket costs are minimal. All the risk and virtually all the cost will borne by Receptor. As they
proceed down the development path and achieve specific developmental goals, we receive
milestone payments in recognition of the increasing value of our technology in their
hands. Again, as is typical, the specific milestones and associated payments are not disclosed
for competitive reasons, but I can say the first material milestone is expected to be received
this year, if all goes according to plan. Total milestones that might be earned total over $100
million, but the real value of this license would come from royalties if successful.
What are MannKind’s responsibilities in the licensing agreement?
MannKind is responsible for transferring necessary technical information about the
Technosphere platform to the licensee and then providing ancillary support as they develop
their product on the Technosphere platform, and ultimately ramp up their manufacturing
capability. To support these efforts, MannKind will name a team of existing scientific and
manufacturing personnel to work with a corresponding team from the licensee, and a project
plan will be implemented to manage the process. We anticipate no incremental costs to
MannKind, just the costs of existing personnel.
What is a proof of concept licensing agreement?
This agreement is described as a proof of concept licensing agreement because it is the first
example of MannKind licensing the Technosphere platform to an independent company for
subsequent product development (in contrast to licensing a product that MannKind has already
taken through development). This agreement creates a business model from which additional
licensing agreements can be designed. The agreement also demonstrates the business
opportunity that exists for Technosphere technology in other pharmaceutical arenas.
Who is the licensing agreement with?
The licensing agreement is between MannKind and Receptor Life Sciences, Inc., an independent
company, not affiliated with MannKind. The company is private and newly formed under this
name. We can confirm that the company is funded by an important investor group, supported
by prominent business leaders in the Seattle area. Alfred Mann is not an investor or in any way
affiliated with Receptor. MannKind did significant diligence in regards to Receptor and its
financial backers, and came away quite impressed. But the underlying investors, for good
reasons of their own, need not and choose not to disclose their involvement at this time.
How will Technosphere technology be used by the licensee?
Technosphere technology is to be used as a vehicle to deliver regulated doses of a proprietary
compound to treat a variety of medical conditions, including chronic pain, spasticity and
inflammatory diseases such as rheumatoid arthritis.
What are the benefits of using MannKind’s technology for the licensee?
Technosphere’s value proposition is the immediate delivery of a consistent and precise dosage
of the prescribed amount of an active therapeutic compound, while reducing unwanted side
effects. In addition, MannKind’s inhalers are convenient, discreet and easy-to-use from
patients’ perspective as well as being a robust and low-cost delivery system from a
manufacturing perspective.
What are the financial terms of the agreement?
Under the terms of the licensing agreement, Mannkind is eligible to receive up to $102.25
million in milestone payments. Additionally, MannKind will receive royalties paid on sales of
the product. Those royalties are tiered based on sales volumes, and range from the mid-single
digits at lower volumes to low double digits at higher volumes.
Is the agreement exclusive in any way?
The agreement is exclusive only to the compounds used by the licensee, which are proprietary
to them in any case. It does not prevent us from entering into other licensing agreements with
other companies, even in the same therapeutic area, so long as they use different active compound.

[sccrbrg]

Jan 21, 2016 20:30:40 GMT -5 cathode said:

Jan 21, 2016 17:18:14 GMT -5 cathode said:

OK, I will bite.

My searches continued to yield one and only one name -- Jeffrey M Herz. In 1997 he was publishing with the affiliation of "Applied Receptor Sciences", but looking at his history of patents, he has worked hand in hand with Omeros Corp -- based in Seattle and a NASDAQ public company. This relation between Mr. Herz and Omeros goes from the mid nineties to current. Mr. Herz is currently the president and CEO of Algomedix Inc, founded in 2010 and based in Mill Creek, WA. He has a history of working on receptor-molecule interactions. These seem to be regarding the inhibition of pain, inflammation, and spasms amongst others.

Some links -- hyperlinks aren't working

www.linkedin.com/in/jeffrey-herz-b5b97b7

www.linkedin.com/in/william-j-thomsen-86009012   <--- Algomedix Director of Pharma
    From the "highlights" of Dr. Thomsen, emphasis added by me:

Hyperlinks are behaving weirdly... copy and paste them.

More on Omeros Corporation:
Their PPS doubled in Aug 2015 when they announced positive results from trials related to the treatment of thrombotic microangiopathies, which are clots of platelets that occur in small blood vessels. This can cause low platelet counts and the rupturing of red blood cells. Their drug works by inhibiting a key pro-inflammatory protein that is part of the immune system. Press Release 2015-08-18

Interesting bits from the press release:

A rare and devastating family of disorders, TMAs are characterized by thrombi or clumps of aggregated platelets in small blood vessels, which lead to thrombocytopenia (below-normal platelet counts) and schistocytes (fragmentation in red blood cells) that can cause dangerously low oxygen levels in organs like the brain and kidney as well as anemia. Thrombotic microangiopathies are life-threatening and can occur both in children and adults. While thrombi, thrombocytopenia and schistocytes are hallmarks of TMAs, other markers of damage within the blood vessels include an elevated plasma lactate dehydrogenase (LDH) and undetectable or reduced plasma haptoglobin levels. In addition, an elevated creatinine level – a result of the kidney damage caused by thrombi – is an indicator of impaired kidney function in patients who are not on renal dialysis.

There have been no confirmed clinically meaningful drug-related adverse events in any clinical trials with OMS721.   [...]   The FDA has cleared OMS721 for chronic dosing in clinical trials.

"We are excited by the data from this Phase 2 clinical trial with OMS721, both with respect to aHUS and TTP patients," stated Gregory A. Demopulos M.D., chairman and chief executive officer of Omeros. "Based on clinical data, we expect that we can deliver OMS721 either subcutaneously or intravenously at a frequency and dose that are both convenient and comfortable for patients while effectively eliminating lectin-pathway activity. Compassionate use in aHUS patients has begun, and we look forward to advancing to the fixed-dose stage of the trial and discussing Phase 3 trial design with the FDA later this year."

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial infection. [...] Omeros has received both Orphan Drug status and Fast Track designation from the U.S. FDA for its lead human MASP-2 antibody OMS721. An ongoing Phase 2 clinical program is evaluating OMS721 in the treatment of thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and stem cell transplant-related TMAs. An investigator-requested compassionate use program for OMS721 is also underway. Chronic toxicity studies with systemically delivered OMS721 demonstrated no drug-related adverse events and, in addition to potential intravenous administration, Omeros plans to commercialize OMS721 for one or more therapeutic indications as a subcutaneous injection.

About Omeros Corporation

Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. [...] Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntington's disease, schizophrenia, and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with urologic surgical procedures.

Dr. Herz has patents with Dr. Demopulos and Omeros Corp primarily related to opthalmologic and urologic applications.

It's entirely possible that I'm wrong, but of the Receptor Life etc's brought up on the board I think this is one of the better candidates.

[sluggobear]

I'd be worried MNKD might put their reputation on the line as a serious drug delivery company by partnering with a THC company. But who knows - could THC or specific cannabinoids be effective for "neurologic diseases" like epilepsy? I saw a news report that a specific CBD strain had been isolated (in CO) and that it was "associated" with stopping severe seizures in children. I haven't researched much other than seeing some news items and websites (e.g. www.cureepilepsy.org/research/cbd-and-epilepsy.asp). But it might explain why the investors want to remain anonymous.

[peppy]

Jan 22, 2016 13:14:16 GMT -5 sluggobear said:

I'd be worried MNKD might put their reputation on the line as a serious drug delivery company by partnering with a THC company. But who knows - could THC or specific cannabinoids be effective for "neurologic diseases" like epilepsy? I saw a news report that a specific CBD strain had been isolated (in CO) and that it was "associated" with stopping severe seizures in children. I haven't researched much other than seeing some news items and websites (e.g. www.cureepilepsy.org/research/cbd-and-epilepsy.asp). But it might explain why the investors want to remain anonymous.

My understanding for epilepsy application, the THC is removed and the cannabinoid that control the epilepsy is used for treatment.

[Deleted]

yes its duplicate x 5 times
time to lock up

[parrerob]

Hey Iam


After suffering centuplications of articles about lawsuite, delisting, sanofy, MNKD not clear with investors..... I think We can keep this duplication at least for today

[cathode]

Jan 22, 2016 13:05:29 GMT -5 sccrbrg said:

It's entirely possible that I'm wrong, but of the Receptor Life etc's brought up on the board I think this is one of the better candidates.

I agree -- here is some more digging on Dr. Herz and Algomedix. There is not much public info available in my googlings.


It seems like Algomedix Inc. is currently an expired entity in Washington, but it may(?) be incorporated in Delaware. Washington State Corporations

Dr. Herz will be giving an address at the Pacific Northwest Biosciences Luncheon on Feb 26, 2016 -- title TBA

Source -- 2012

—Algomedix, founded by pharmacologist Jeff Herz, is pursuing a new idea in the treatment of pain. There hasn’t been much in the way of innovation in pain treatment, and existing drugs like opioids and COX-2 inhibitors all have their drawbacks, like addiction and cardiovascular side effects. The idea at Algomedix is to make small-molecule drugs that block a target called TRPA1, a receptor channel that allows ions like salts to pass in and out of cells. This target, Herz said, gets involved early in the pain signaling process, before a signal makes its way to the spinal cord and brain.

Herz, the former director of discovery research at Seattle-based Omeros (NASDAQ: OMER), said he’s particularly intrigued with the TRPA1 target, because while it’s found in many tissues of the body, it’s not found in the brain. That means that a drug which blocks the target shouldn’t cause any of the usual central-nervous system side effects, like addiction, that cause so much trouble for people taking opioid. Based on the work done so far to develop drugs against the target, Algomedix expects to file its first application to start clinical trials in early 2014, Herz said. Given the size of the market is for chronic pain, which afflicts millions of people around the world, Big Pharma has already started to notice, Herz said. “We see this as a highly partnerable program. We have already had expressions of interest from a number of companies,” he said

Source -- 2014

The speaker for this presentation was Jeffrey M. Herz, PhD, President and CEO, who focused the discussion on targeting TRP channels for treatment of chronic pain, inflammation, and chronic kidney disease.

Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation. More than 100 million Americans suffer from chronic pain. Existing chronic pain therapies based on opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are inadequate at addressing patient and physician needs and constitute a regulatory issue for the FDA. Use of these existing medicines presents significant safety, tolerability, abuse, and addiction concerns that limit use. A major unmet medical need is an effective therapeutic for chronic pain that is devoid of both addictive potential and abuse liability. Algomedix has discovered and is developing a novel non-opiod drug that solves these problems.

The company’s approach to pain relief focuses on blocking pain at its source in the peripheral nervous system, developing drugs that act as analgesics by a defined mechanism of action. Algomedix has three drugs in clinical trials and is looking for partnerships to help commercialize both its chronic pain and chronic kidney disease programs.

SBIRSource

Selected Algomedix Grants can be found here as well

Analgesics Targeting TRPA1 for Treatment of Chronic Pain -- 2013-2014

Control of Arthritic Pain by Inhibition of TRPA1 Activity -- 2011-2013

Looks like they have received a grant from the National Institute of Drug Abuse for studying their compound applied for chronic pain.

[sccrbrg]

Jan 22, 2016 15:27:36 GMT -5 cathode said:

Jan 22, 2016 13:05:29 GMT -5 sccrbrg said:

It's entirely possible that I'm wrong, but of the Receptor Life etc's brought up on the board I think this is one of the better candidates.

I agree -- here is some more digging on Dr. Herz and Algomedix. There is not much public info available in my googlings.


It seems like Algomedix Inc. is currently an expired entity in Washington, but it may(?) be incorporated in Delaware. Washington State Corporations

Dr. Herz will be giving an address at the Pacific Northwest Biosciences Luncheon on Feb 26, 2016 -- title TBA

Source -- 2012

—Algomedix, founded by pharmacologist Jeff Herz, is pursuing a new idea in the treatment of pain. There hasn’t been much in the way of innovation in pain treatment, and existing drugs like opioids and COX-2 inhibitors all have their drawbacks, like addiction and cardiovascular side effects. The idea at Algomedix is to make small-molecule drugs that block a target called TRPA1, a receptor channel that allows ions like salts to pass in and out of cells. This target, Herz said, gets involved early in the pain signaling process, before a signal makes its way to the spinal cord and brain.

Herz, the former director of discovery research at Seattle-based Omeros (NASDAQ: OMER), said he’s particularly intrigued with the TRPA1 target, because while it’s found in many tissues of the body, it’s not found in the brain. That means that a drug which blocks the target shouldn’t cause any of the usual central-nervous system side effects, like addiction, that cause so much trouble for people taking opioid. Based on the work done so far to develop drugs against the target, Algomedix expects to file its first application to start clinical trials in early 2014, Herz said. Given the size of the market is for chronic pain, which afflicts millions of people around the world, Big Pharma has already started to notice, Herz said. “We see this as a highly partnerable program. We have already had expressions of interest from a number of companies,” he said

Source -- 2014

The speaker for this presentation was Jeffrey M. Herz, PhD, President and CEO, who focused the discussion on targeting TRP channels for treatment of chronic pain, inflammation, and chronic kidney disease.

Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation. More than 100 million Americans suffer from chronic pain. Existing chronic pain therapies based on opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are inadequate at addressing patient and physician needs and constitute a regulatory issue for the FDA. Use of these existing medicines presents significant safety, tolerability, abuse, and addiction concerns that limit use. A major unmet medical need is an effective therapeutic for chronic pain that is devoid of both addictive potential and abuse liability. Algomedix has discovered and is developing a novel non-opiod drug that solves these problems.

The company’s approach to pain relief focuses on blocking pain at its source in the peripheral nervous system, developing drugs that act as analgesics by a defined mechanism of action. Algomedix has three drugs in clinical trials and is looking for partnerships to help commercialize both its chronic pain and chronic kidney disease programs.

SBIRSource

Selected Algomedix Grants can be found here as well

Analgesics Targeting TRPA1 for Treatment of Chronic Pain -- 2013-2014

Control of Arthritic Pain by Inhibition of TRPA1 Activity -- 2011-2013

Looks like they have received a grant from the National Institute of Drug Abuse for studying their compound applied for chronic pain.

Sounds like a pretty good candidate for a technosphere partner to me.

Thanks for doing all of the legwork on this one!

[sccrbrg]

Algomedix is indeed incorporated in Delaware:


THIS IS NOT A STATEMENT OF GOOD STANDING

File Number: 4759223 Incorporation Date / Formation Date: 12/1/2009

(mm/dd/yyyy)

Entity Name: ALGOMEDIX, INC.

Entity Kind: Corporation Entity Type: General

Residency: Domestic State: DELAWARE

REGISTERED AGENT INFORMATION

Name: NATIONAL REGISTERED AGENTS, INC.

Address: 160 GREENTREE DR STE 101

City: DOVER County: Kent

State: DE Postal Code: 19904

Phone: [phone]

[Deleted]

Jan 22, 2016 15:27:36 GMT -5 cathode said:

Jan 22, 2016 13:05:29 GMT -5 sccrbrg said:

will that fit ?

" We can confirm that the company is funded by an important investor group, supported

by prominent business leaders in the Seattle area"

[kbrion77]

Jan 22, 2016 16:19:55 GMT -5 @iam2sekc4u2002 said:

Jan 22, 2016 15:27:36 GMT -5 cathode said:

will that fit ?

" We can confirm that the company is funded by an important investor group, supported

by prominent business leaders in the Seattle area"

Can't help but think Steven Gillis and Robert Nelsen of Arch Venture Partners are somehow involved.  Maybe wishful thinking but just my opinion.  I actually like Nelsen, how about this tweet from his twitter handle from September 2015:

"Future health system will have few, niche hospitals--disease will be diagnosed and treatments designed real-time in office or even home."

Does the above sound familiar?

www.archventure.com/team/robert_nelsen.html

www.archventure.com/team/steve_gillis.html

www.xconomy.com/seattle/2009/09/23/biotech-pioneer-steve-gillis-on-life-as-a-vc-how-todays-entrepreneurs-can-make-it-and-seattles-future-in-life-sciences-part-1/?single_page=true

medcitynews.com/2014/08/arch-venture-partners-plans-fund-wild-ass-ideas-new-400-million-venture-fund/

[harryx1]

[lorcan458]

I sent a message titled "Welcome to the Technosphere" with the following message:

As I'm sure you know, Mannkind has a loyal and enthusiastic base of diabetics whose lives are far better because of Afrezza and a long suffering, yet ever hopeful group of retail investors that look forward to a bright future. Show your backing of Mannkind and you will have the backing of the Afrezza Army. We can change the world together.

By the way, if you've already picked up some shares of MNKD, please feel free to initiate a short squeeze and help us give the Martin Shkrelis of the world a hard kick in the balls. Thanks!

[mindovermatter]

Jan 22, 2016 20:02:35 GMT -5 harryx1 said:

Ditto robo response (posted below) for me as I wrote, "If you do not tell me what your plans are this instant, my wife is going to beat me senseless."   

They must have sent out hundreds of emails with the same info


Thank you for your interest in Receptor Life Sciences. We are pleased to be partnering with MannKind to deliver inhaled therapeutics utilizing their innovative platform. Our work is proceeding rapidly and we will look forward to sharing more exciting news with you as our activities become public.

Thank you again,

The Receptor Team